VERTEX PHARMACEUTICALS INC (VRTX) Stock Price, Quote, News and Overview
NASDAQ:VRTX - Nasdaq - US92532F1003 - Common Stock - Currency: USD
VRTX Quote, Performance and Key Statistics
481.65
-2.59 (-0.53%)
The current stock price of VRTX is 481.65 USD. In the past month the price increased by 9.56%. In the past year, price increased by 11.3%.
VRTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.17 | 360.64B | ||
| AMGN | AMGEN INC | 15.63 | 166.32B | ||
| GILD | GILEAD SCIENCES INC | 24.08 | 138.34B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.63 | 77.97B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.11B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.04B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.58B | ||
| NTRA | NATERA INC | N/A | 20.91B | ||
| BIIB | BIOGEN INC | 8.58 | 20.59B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.73 | 15.99B | ||
| INCY | INCYTE CORP | 56.07 | 14.32B |
Related stock screener links
About VRTX
Company Profile
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 5,400 full-time employees. The firm is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. The company has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The company is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.
Company Info
VERTEX PHARMACEUTICALS INC
50 Northern Avenue
Boston MASSACHUSETTS 02210 US
CEO: Reshma Kewalramani
Employees: 5400
Company Website: https://www.vrtx.com/
Investor Relations: https://investors.vrtx.com/
Phone: 16173416393
VERTEX PHARMACEUTICALS INC / VRTX FAQ
What is the stock price of VERTEX PHARMACEUTICALS INC today?
The current stock price of VRTX is 481.65 USD. The price decreased by -0.53% in the last trading session.
What is the ticker symbol for VERTEX PHARMACEUTICALS INC stock?
The exchange symbol of VERTEX PHARMACEUTICALS INC is VRTX and it is listed on the Nasdaq exchange.
On which exchange is VRTX stock listed?
VRTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VERTEX PHARMACEUTICALS INC stock?
40 analysts have analysed VRTX and the average price target is 512.92 USD. This implies a price increase of 6.49% is expected in the next year compared to the current price of 481.65. Check the VERTEX PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VERTEX PHARMACEUTICALS INC worth?
VERTEX PHARMACEUTICALS INC (VRTX) has a market capitalization of 123.74B USD. This makes VRTX a Large Cap stock.
How many employees does VERTEX PHARMACEUTICALS INC have?
VERTEX PHARMACEUTICALS INC (VRTX) currently has 5400 employees.
What are the support and resistance levels for VERTEX PHARMACEUTICALS INC (VRTX) stock?
VERTEX PHARMACEUTICALS INC (VRTX) has a support level at 468.01 and a resistance level at 482.58. Check the full technical report for a detailed analysis of VRTX support and resistance levels.
Is VERTEX PHARMACEUTICALS INC (VRTX) expected to grow?
The Revenue of VERTEX PHARMACEUTICALS INC (VRTX) is expected to grow by 9.77% in the next year. Check the estimates tab for more information on the VRTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VERTEX PHARMACEUTICALS INC (VRTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VRTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VRTX, evaluating the profitability, health, valuation and growth aspects
- VERTEX PHARMACEUTICALS INC (VRTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VERTEX PHARMACEUTICALS INC (VRTX) Sales and EPS estimates to see what analysts future expectations are.
- VERTEX PHARMACEUTICALS INC (VRTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VERTEX PHARMACEUTICALS INC (VRTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- VERTEX PHARMACEUTICALS INC (VRTX) Stock Chart to make your own analysis
- VERTEX PHARMACEUTICALS INC (VRTX) Latest news and press-releases to stay up to date.
Does VERTEX PHARMACEUTICALS INC (VRTX) stock pay dividends?
VRTX does not pay a dividend.
When does VERTEX PHARMACEUTICALS INC (VRTX) report earnings?
VERTEX PHARMACEUTICALS INC (VRTX) will report earnings on 2025-05-05, after the market close.
What is the Price/Earnings (PE) ratio of VERTEX PHARMACEUTICALS INC (VRTX)?
The PE ratio for VERTEX PHARMACEUTICALS INC (VRTX) is 1660.86. This is based on the reported non-GAAP earnings per share of 0.29 and the current share price of 481.65 USD. Check the full fundamental report for a full analysis of the valuation metrics for VRTX.
What is the Short Interest ratio of VERTEX PHARMACEUTICALS INC (VRTX) stock?
The outstanding short interest for VERTEX PHARMACEUTICALS INC (VRTX) is 1.78% of its float. Check the ownership tab for more information on the VRTX short interest.
VRTX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to VRTX. When comparing the yearly performance of all stocks, VRTX is one of the better performing stocks in the market, outperforming 73.99% of all stocks.
VRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to VRTX. While VRTX has a great profitability rating, there are some minor concerns on its financial health.
VRTX Financial Highlights
Over the last trailing twelve months VRTX reported a non-GAAP Earnings per Share(EPS) of 0.29. The EPS decreased by -98.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.38% | ||
| ROE | -3.26% | ||
| Debt/Equity | 0.01 |
VRTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to VRTX. The Buy consensus is the average rating of analysts ratings from 40 analysts.
For the next year, analysts expect an EPS growth of 6237.42% and a revenue growth 9.77% for VRTX